All articles by Drug Target Review – Page 47
-
NewsImproving cancer treatment by exploiting mtDNA mutations
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
-
News
Novel prediction tool accurately determines disease stage
A new learning-based framework enables patients and caregivers to predict the timing of any of the five clinical groups of AD development.
-
News
Targeting Ku70 could improve bowel cancer treatment
The Ku70 protein prevents cancer cells from becoming more aggressive and metastasising. It could also be used as an immune biomarker.
-
ArticleNavigating the neurological frontier - 2024 and beyond
Listen to this podcast where we step into the new year and explore research insights and projections for the field in 2024 in neuroscience.
-
ReportBeyond the lab: stem cell research
Download this report to discover more about human derived induced pluripotent stem cells (hiPSCs), the suitability of NK cells for cancer therapy and the latest research into Alzheimer’s disease.
-
NewsX-ray irradiation reversed motor deficits after brain injury
Low dose ionising radiation reduced lesion size and reversed motor deficits in traumatic brain injury and ischemic stroke mice.
-
News
CRISPR activation: quicker diagnosis of rare genetic diseases
Using CRISPRa to activate genes in readily accessible cells provides an effective and accurate diagnosis of genetic diseases.
-
NewsHow the HIV capsid has evolved into a molecular transporter
The discovery that HIV capsids are importin-like transporters could be exploited for improved AIDS therapies.
-
NewsNew immunological pathway to treat bone tumours
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
-
NewsThe potential of PD-L2 inhibitors for cancer treatment
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
-
News
PLK4 inhibition: a new therapeutic for AML
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
-
NewsAdvancing personalised medicine with a cholangiocarcinoma model
A patient-specific organ-on-a-chip model of cholangiocarcinoma, with its tumour microenvironment, helps to predict therapy response.
-
NewsHow PD-1 promotes Merkel cell carcinoma progression
Inhibiting mTOR signalling and neutralising mtROS suppressed MCC-PD-1-mediated tumour proliferation in mice.
-
NewsOff-switches developed for CRISPR-Cas3 technologies
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
-
NewsKnockdown of FAM3C inhibits breast cancer tumour growth
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
-
NewsStudying the effects of 3D genome organisation on gene silencing
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
-
News
New algorithm can predict when cancer will resist chemotherapy
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
-
News
Blocking the IL-6 receptor to protect tissues from CRS
The new study’s findings suggest that CRS can be treated with an IL-6 receptor antibody that has a short half-life.
-
NewsIPSCs used to study common genetic cause of chILD
Researchers observed many quantifiable differences between diseased cells made from affected children and their gene-edited cells.
-
NewsFinding the fundamental pathway in ALD pathogenesis
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.